SPECIAL REPORT #12
The US FDA Commissioner Scott Gottlieb resign from his post on 5 March, effective one month from today.
The resignation of Scott Gottlieb took Capitol Hill and the biopharmaceutical industry by surprise as he had pushed back earlier speculation about him leaving the agency.
Under his tenure, which started in May 2017, the US FDA has approved record numbers of innovative drugs, generics as well as new medical devices and has tacken action to boost price transparency.
More recently, he publicly criticized the anti-vaccination movement, indicating he was willing to combat the trend from a federal level. Since last fall Gottlieb also pushed hard to ban menthol-flavored cigarettes in addition to flavor the vaping devices.
House Energy and Commerce ranking member Greg Walden, said he has” never worked with a more talented forthright and effective agency leader than Dr. Scott Gootlieb”
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.